Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life
This post hoc analysis demonstrated that patients treated with erenumab had significant improvements in headache impact and quality of life as measured by patient-reported outcomes versus patients treated with topiramate.
Authors
- Christian Sieder
- Christian Hentschke
- Astrid Gendolla (ORCID: https://orcid.org/0000-0002-9884-3158)
- Uwe Reuter (ORCID: https://orcid.org/0000-0002-8527-0725)
- Axel Heinze (ORCID: https://orcid.org/0009-0001-7780-4301)
Institutions
- Universitätsmedizin Greifswald (DE)
- Novartis (Germany) (DE)
- Schmerzklinik Kiel (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1111/ene.16437
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Novartis Pharma